News —
Summary
Financing will expand the companys High Dimensional Design of Experiments platform (HD-DoE), support the generation of multiple specialized human cells with therapeutic properties and their pilot scale manufacturing CLEVELAND, Nov. 10, 2020 /PRNewswire/ -- Trailhead Biosystems Inc. - a biotechnology company pioneering the application of machine-enabled science towards understanding and controlling biology - announced its $6.6 million Series A financing. The company has developed a proprietary platform to perform systems-level interrogation of complex biological problems, ranging from the generation of industrially-scalable manufacturing conditions for specialized human cells to combinatorial drug discovery in cancer and anti-viral therapies. "We created Trailhead Biosystems to address key limitations in the scientific process, unlocking a deeper understanding of biology that will enable us to better control it." "Trailhead is a key enabling technology developer who works closely with the Advanced Regenerative Manufacturing Institute (ARMI)," through the BioFabUSA program, Tom Bollenbach, Chief Technical Officer, says. Magnus Persson, M.D., PhD, a seasoned biotech entrepreneur and Chairman of the Board of Trailhead Biosystems reflects on the path ahead: "I am extremely proud to have helped put Trailhead Biosystems on a path to enable Jans extraordinary out-of the-box science to discover therapeutics that could potentially alleviate conditions that lack a cure today.